title: Leukaemias into the 21st century. Part 2: the chronic leukaemias.
abstract: Like the acute leukaemias, the chronic leukaemias are broadly classified according to their cell lineage of origin. Chronic myeloid leukaemia and chronic lymphocytic leukaemia are the most common disease entities within the myeloid and lymphoid lineages, although several less common entities are well recognised within each broad subgroup. In common with the dramatic progress in the acute leukaemias, there has been considerable progress in our understanding of the biology and molecular genetics of the chronic leukaemias that is now being translated into significant therapeutic advances.
authors.affiliation: Institute of Haematology, Royal Prince Alfred Hospital and University of Sydney, Sydney, NSW, Australia. john.gibson@sswahs.nsw.gov.au
authors.forename: J
authors.initials: J
authors.lastname: Gibson
authors.forename: H J
authors.initials: HJ
authors.lastname: Iland
authors.forename: S R
authors.initials: SR
authors.lastname: Larsen
authors.forename: C M S
authors.initials: CM
authors.lastname: Brown
authors.forename: D E
authors.initials: DE
authors.lastname: Joshua
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use; D019468:Disease Management; D005544:Forecasting; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000175:diagnosis* / Q000453:epidemiology / Q000628:therapy*; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000175:diagnosis* / Q000453:epidemiology / Q000628:therapy*
chemical_list: D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents